1[1]Dabelea D, Pettitt DJ, Jones KL, et al. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem[J]. Endocrinol Metab Clin North Am, 1999,28(4): 709-729.
2[2]Friedman EA . Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications[J]. Diabetes Care, 1999, 22(suppl 2): B65-B71.
3[3]Lobner K, Khoo-Morgenthaler UY, Seissler J, et al. Detection of autoantibodies to the diabetes-associated antigen IA-2 by a sensitive enzyme-linked immunosorbent assay[J]. Horm Metab Res, 1999, 31(12): 686-691.
4[4]Toivonen A, Kulmala P, Savola K, et al. Soluble adhesion molecules in preclinical type 1 diabetes [J]. Pediatr Res,2001, 49(1): 24-29.
5[6]Wang Y, Xu A, Knight C, et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity [J]. J Biol Chem, 2002, 277(22):19521-19529.
6[7]Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization[J]. Endocrinology,2002,143(3):998-1007.
7[8]Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes[J]. Metabolism,2002,51(3):314-317.
8[9]Bakker SJ, IJzerman RG, Teerlink T, et al. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure[J]? Atherosclerosis,2000,148(1):17-21.
